These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Behm BW; Bickston SJ Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120 [TBL] [Abstract][Full Text] [Related]
27. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy. Miler M; Nikolac Gabaj N; Ćelap I; Grazio S; Tomašić V; Bišćanin A; Mitrović J; Đerek L; Morović-Vergles J; Vrkić N; Štefanović M Rheumatol Int; 2021 Dec; 41(12):2195-2203. PubMed ID: 34623480 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study. Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614 [TBL] [Abstract][Full Text] [Related]
29. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Chiu YL; Rubin DT; Vermeire S; Louis E; Robinson AM; Lomax KG; Pollack PF; Paulson SK Inflamm Bowel Dis; 2013 May; 19(6):1112-22. PubMed ID: 23584130 [TBL] [Abstract][Full Text] [Related]
30. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study. Little RD; Swaine A; Reynolds R; Gibson DJ; Barrau M; D'Errico F; Hampal R; Sparrow MP; Roblin X; Irving PM; Ward MG Inflamm Bowel Dis; 2023 Nov; ():. PubMed ID: 37951220 [TBL] [Abstract][Full Text] [Related]
31. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965 [TBL] [Abstract][Full Text] [Related]
32. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS; Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032 [TBL] [Abstract][Full Text] [Related]
33. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Kiss LS; Szamosi T; Molnar T; Miheller P; Lakatos L; Vincze A; Palatka K; Barta Z; Gasztonyi B; Salamon A; Horvath G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovasz BD; Vegh Z; Golovics PA; Szathmari M; Papp M; Lakatos PL; Aliment Pharmacol Ther; 2011 Oct; 34(8):911-22. PubMed ID: 21883326 [TBL] [Abstract][Full Text] [Related]
35. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease. Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158 [TBL] [Abstract][Full Text] [Related]
36. [Adalimumab as induction therapy for Crohn's disease - one center study]. Gonciarz M; Mularczyk A; Szkudłapski D; Piątek I; Kopała M Pol Merkur Lekarski; 2016 Nov; 41(245):216-220. PubMed ID: 27883347 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766 [TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857 [TBL] [Abstract][Full Text] [Related]
39. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study. Levine A; Turner D; Pfeffer Gik T; Amil Dias J; Veres G; Shaoul R; Staiano A; Escher J; Kolho KL; Paerregaard A; Martin de Carpi J; Veereman Wauters G; Koletzko S; Shevah O; Finnby L; Sladek M Inflamm Bowel Dis; 2014 Feb; 20(2):278-85. PubMed ID: 24390062 [TBL] [Abstract][Full Text] [Related]
40. Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. Duveau N; Nachury M; Gerard R; Branche J; Maunoury V; Boualit M; Wils P; Desreumaux P; Pariente B Dig Liver Dis; 2017 Feb; 49(2):163-169. PubMed ID: 27899263 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]